Dicerna Pharmaceuticals (NASDAQ:DRNA)‘s stock had its “neutral” rating reissued by equities research analysts at Chardan Capital in a research note issued to investors on Tuesday.

Several other equities analysts have also commented on the company. HC Wainwright restated a “buy” rating and set a $10.00 price target (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. Zacks Investment Research raised Dicerna Pharmaceuticals from a “strong sell” rating to a “buy” rating and set a $6.25 price objective on the stock in a research report on Monday, October 23rd. ValuEngine raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, November 2nd. BidaskClub downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Evercore ISI started coverage on Dicerna Pharmaceuticals in a research report on Tuesday. They set an “outperform” rating and a $14.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $8.25.

Dicerna Pharmaceuticals (NASDAQ DRNA) opened at $8.83 on Tuesday. The company has a market capitalization of $463.22, a price-to-earnings ratio of -2.57 and a beta of 2.85. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.22). The firm had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The company’s revenue for the quarter was up 192.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.68) EPS. analysts forecast that Dicerna Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.

In related news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were bought at an average price of $7.00 per share, with a total value of $1,995,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 29.41% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Northern Trust Corp boosted its position in Dicerna Pharmaceuticals by 6.1% during the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares in the last quarter. Birchview Capital LP boosted its holdings in Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 25,000 shares in the last quarter. Deschutes Portfolio Strategy LLC acquired a new stake in Dicerna Pharmaceuticals in the third quarter worth about $575,000. Vanguard Group Inc. boosted its holdings in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 14,517 shares in the last quarter. Finally, Palo Alto Investors LLC boosted its holdings in Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after acquiring an additional 19,394 shares in the last quarter. 21.93% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals (DRNA) Given Neutral Rating at Chardan Capital” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/20/dicerna-pharmaceuticals-drna-given-neutral-rating-at-chardan-capital.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.